ncRNA basic information
ncRNA ID:
NA
ncRNA Database:
miRBase
ncRNA Name:
miR-181
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
NA
ncRNA Pathway:
PTEN/PI3K/AKT pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The aim of the present study was to investigate the effect of miR-181 on cisplatin-resistant non-small cell lung cancer (NSCLC). In patients with cisplatin-resistant NSCLC, miR-181 expression was found to be markedly decreased. In addition, in the cisplatin-resistant human lung adenocarcinoma cell line A549/DDP, miR-181 downregulation promoted cell growth and metastasis and inhibited cell apoptosis, whereas miR-181 overexpression exerted the opposite effects. Furthermore, miR-181 downregulation suppressed LC3 and ATG5 protein expression in A549/DDP cells through suppression of the PTEN/PI3K/AKT/mTOR pathway, whereas miR-181 overexpression recovered LC3 and ATG5 protein expression by promoting PTEN/PI3K/AKT/mTOR signaling. In turn, PTEN inhibitors reduced the anticancer effects of miR-181 overexpression on A549/DDP cell growth via the regulation of autophagy through the PI3K/AKT/mTOR pathway.
Drug Response:
resistant
Cancer basic information
Cancer:
lung non-small cell carcinoma
Tissue/Cell:
cell line (A549/DDP)
Other information
Title:
miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
Journal:
Oncol Rep
Published:
2018
PubMed ID:
29484437